stockrowAstraZeneca PLC (AZN) vs Bristol Myers Squibb Company (BMY)
- AstraZeneca PLC AZN 186.05 −0.43%
- Bristol Myers Squibb Company BMY 62.46 −1.06%
AstraZeneca PLC and Bristol Myers Squibb Company are both Drug Manufacturers General companies. AstraZeneca PLC is the larger, with a market value of $289.8B against $129.0B — 2.2× the size. Bristol Myers Squibb Company trades at the lower P/E: 14.0× against 26.3×. AstraZeneca PLC grew revenue faster over the last twelve months: 7.32% against 4.16%. Bristol Myers Squibb Company has the higher net margin (18.5% vs 17.7%) and the higher return on invested capital (13.2% vs 12.3%). Both pay a dividend; Bristol Myers Squibb Company yields more (3.99% vs 1.71%). Across the 23 metrics below, Bristol Myers Squibb Company leads on 16 and AstraZeneca PLC on 7.
Valuation
Profitability
| Metric | AZN | BMY | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 81.94% | 69.24% | 73.01% |
| Operating margin | 23.68% | 22.65% | 18.34% |
| Net margin | 17.68% | 18.47% | 7.31% |
| Free cash flow margin | 10.15% | 18.56% | 18.52% |
| Return on equity | 22.56% | 44.01% | 5.80% |
| Return on assets | 9.41% | 9.96% | 2.28% |
| Return on invested capital | 12.31% | 13.19% | 6.26% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack